Co-Target(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T74363 | Target Info | |||
| Target Name | Urokinase plasminogen activator surface receptor (PLAUR) | ||||
| Synonyms |
Urokinase-type plasminogen activator receptor; Urokinase plasminogen activator receptor; Monocyte activation antigenMo3; CD87 antigen; CD87
Click to Show/Hide
|
||||
| Target Type | Successful Target | ||||
| Gene Name | PLAUR | ||||
| UniProt ID | |||||
| Co-Targets of This Target | Top | |||||
|---|---|---|---|---|---|---|
| Co-Target Name | Janus kinase 2 (JAK-2) | Successful Target | ||||
| UniProt ID | JAK2_HUMAN | |||||
| Gene Name | JAK2 | |||||
| Synonyms |
Tyrosine-protein kinase JAK2
Click to Show/Hide
|
|||||
| Representative Drug(s) | Ruxolitinib | Drug Info | IC50 = 0.056 nM | Click to Show More | [1] | |
| 2 | Ruxolitinib | Drug Info | IC50 ~ 100 nM | [4] | ||
| Co-Target Name | Janus kinase 1 (JAK-1) | Successful Target | ||||
| UniProt ID | JAK1_HUMAN | |||||
| Gene Name | JAK1 | |||||
| Synonyms |
Tyrosine-protein kinase JAK1; JAK1B; JAK1A
Click to Show/Hide
|
|||||
| Representative Drug(s) | Ruxolitinib | Drug Info | Ki = 0.09 nM | Click to Show More | [2] | |
| 2 | Ruxolitinib | Drug Info | IC50 ~ 100 nM | [4] | ||
| Co-Target Name | Janus kinase 3 (JAK-3) | Successful Target | ||||
| UniProt ID | JAK3_HUMAN | |||||
| Gene Name | JAK3 | |||||
| Synonyms |
Tyrosine-protein kinase JAK3; Leukocyte janus kinase; L-JAK
Click to Show/Hide
|
|||||
| Representative Drug(s) | Ruxolitinib | Drug Info | IC50 = 2.8 nM | Click to Show More | [3] | |
| 2 | Ruxolitinib | Drug Info | IC50 ~ 100 nM | [4] | ||
| Co-Target Name | TYK2 tyrosine kinase (TYK2) | Successful Target | ||||
| UniProt ID | TYK2_HUMAN | |||||
| Gene Name | TYK2 | |||||
| Synonyms |
Non-receptor tyrosine-protein kinase TYK2
Click to Show/Hide
|
|||||
| Representative Drug(s) | Ruxolitinib | Drug Info | IC50 = 0.4 nM | Click to Show More | [5] | |
| 2 | Ruxolitinib | Drug Info | IC50 ~ 100 nM | [4] | ||
| Co-Target Name | Histone deacetylase 6 (HDAC6) | Clinical trial Target | ||||
| UniProt ID | HDAC6_HUMAN | |||||
| Gene Name | HDAC6 | |||||
| Synonyms |
KIAA0901; JM21; HD6
Click to Show/Hide
|
|||||
| Representative Drug(s) | Ruxolitinib | Drug Info | IC50 = 15 nM | [6] | ||
| Co-Target Name | Tyrosine protein kinase JAK1-Tyrosine protein kinase JAK3 complex (JAK1-JAK3) | Co-Target | ||||
| UniProt ID | JAK3_HUMAN-JAK1_HUMAN | |||||
| Gene Name | JAK1-JAK3 | |||||
| Representative Drug(s) | Ruxolitinib | Drug Info | IC50 = 23 nM | [7] | ||
| Co-Target Name | Tyrosine protein kinase JAK1-Tyrosine protein kinase JAK2 complex (JAK1-JAK2) | Co-Target | ||||
| UniProt ID | JAK1_HUMAN-JAK2_HUMAN | |||||
| Gene Name | JAK2-JAK1 | |||||
| Representative Drug(s) | Ruxolitinib | Drug Info | IC50 = 31 nM | [7] | ||
| Co-Target Name | Tyrosine protein kinase JAK1-Non receptor tyrosine protein kinase TYK2 (JAK1-TYK2) | Co-Target | ||||
| UniProt ID | JAK1_HUMAN-TYK2_HUMAN | |||||
| Gene Name | JAK1-TYK2 | |||||
| Representative Drug(s) | Ruxolitinib | Drug Info | IC50 = 194 nM | [8] | ||
| Co-Target Name | JAK1-JAK2-TYK2 complex (JAK1-JAK2-TYK2) | Co-Target | ||||
| UniProt ID | JAK1_HUMAN-JAK2_HUMAN-TYK2_HUMAN | |||||
| Gene Name | JAK1-JAK2-TYK2 | |||||
| Representative Drug(s) | Ruxolitinib | Drug Info | IC50 = 298 nM | [8] | ||
| Co-Target Name | Tyrosine protein kinase JAK2-Non receptor tyrosine protein kinase TYK2 complex (JAK2-TYK2) | Co-Target | ||||
| UniProt ID | JAK2_HUMAN-TYK2_HUMAN | |||||
| Gene Name | JAK2-TYK2 | |||||
| Representative Drug(s) | Ruxolitinib | Drug Info | IC50 = 818 nM | [8] | ||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. J Med Chem. 2017 Oct 26;60(20):8336-57. | ||||
| REF 2 | Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors. J Med Chem. 2012 Nov 26;55(22):10090-107. | ||||
| REF 3 | Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors. Bioorg Med Chem Lett. 2016 Apr 1;26(7):1803-8. | ||||
| REF 4 | Inhibitors of Stat5 protein signalling. Medchemcomm. 2012;3:22-7. | ||||
| REF 5 | Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors. Bioorg Med Chem Lett. 2014 Feb 15;24(4):1116-21. | ||||
| REF 6 | Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. J Med Chem. 2019 Apr 25;62(8):3898-3923. | ||||
| REF 7 | Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome. Bioorg Med Chem Lett. 2013 May 1;23(9):2793-800. | ||||
| REF 8 | Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014 Jun 26;57(12):5023-38. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.